Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study
Tóm tắt
Extraskeletal myxoid chondrosarcoma (EMC) is a rare subgroup within soft tissue sarcomas. Its sensitivity to chemotherapy is reported to be low. We retrospectively reviewed a series of 11 EMC patients treated as from 2001 within the Italian Rare Cancer Network (RCN) with anthracycline-based chemotherapy. Pathologic diagnosis was centrally reviewed in all cases and confirmed by the presence of the specific chromosomal rearrangements, involving the NR4A3 gene locus on chromosome 9. Eleven patients treated with anthracycline-based chemotherapy were included (M/F: 9/2 – mean age: 52 years – site of primary: lower limb/other = 9/2 - metastatic = 11 – front line/ further line = 10/1 – anthracycline as single agent/ combined with ifosfamide = 1/10). Ten patients are evaluable for response. Overall, best response according to RECIST was: partial response (PR) = 4 (40 %), stable disease (SD) = 3, progressive disease (PD) = 3 cases. Median PFS was 8 (range 2–10) months. By contrast to what reported so far, anthracycline-based chemotherapy is active in a distinct proportion of EMC patients.
Tài liệu tham khảo
Fletcher CDM: eds. World Health Organization (WHO) Classification of Tumours of Soft tissue and Bone. Pathology and Genetics. 2013, Lyon: IARC Press,
Meis-Kindblom JM, Bergh P, Gunterberg B, Kindblom LG: Extraskeletal myxoid chondrosarcoma: a reappraisal of its morphologic spectrum and prognostic factors based on 117 cases. Am J Surg Pathol. 1999, 23: 636-650. 10.1097/00000478-199906000-00002
Demicco EG, Wang WL, Madewell JE, Huang D, Bui MM, Bridge JA, Meis JM: Osseous myxochondroid sarcoma: a detailed study of 5 cases of extraskeletal myxoid chondrosarcoma of the bone. Am J Surg Pathol. 2013, 37: 752-762. 10.1097/PAS.0b013e3182796e46
Antonescu CR, Argani P, Erlandson RA: Skeletal and extraskeletal myxoid chondrosarcoma: a comparative clinicopathologic, ultrastructural, and molecular study. Cancer. 1998, 83: 1504-1521. 10.1002/(SICI)1097-0142(19981015)83:8<1504::AID-CNCR5>3.0.CO;2-B
Hinrichs SH, Jaramillo MA, Gumerlock PH: Myxoid chondrosarcoma with a translocation involving chromosomes 9 and 22. Cancer Genet Cytogenet. 1985, 14: 219-226. 10.1016/0165-4608(85)90187-6
Hirabayashi Y, Ishida T, Yoshida MA: Translocation (9;22)(q22;q12). A recurrent chromosome abnormality in extraskeletal myxoid chondrosarcoma. Cancer Genet Cytogenet. 1995, 81: 33-37. 10.1016/0165-4608(94)00201-0
Stenman G, Andersson H, Mandahl N, Meis-Kindblom JM, Kindblom LG: Translocation t(9;22)(q22;q12) is a primary cytogenetic abnormality in extraskeletal myxoid chondrosarcoma. Int J Cancer. 1995, 62: 398-402. 10.1002/ijc.2910620407
Sjögren H, Meis-Kindblom J, Kindblom LG: Fusion of the EWS-related gene TAF2N to TEC in extraskeletal myxoid chondrosarcoma. Cancer Res. 1999, 59: 5064-5067.
Sjögren H, Wedell B, Meis-Kindblom JM, Kindblom LG, Stenman G: Fusion of the NH2-terminal domain of the basic helix-loop-helix protein TCF12 to TEC in extraskeletal myxoid chondrosarcoma with translocation t(9;15)(q22;q21). Cancer Res. 2000; 60:6832–5. Erratum in. Cancer Res. 2001, 61: 2339-
Flucke U, Tops BB, Verdijk MA: NR4A3 rearrangement reliably distinguishes between the clinicopathologically overlapping entities myoepithelial carcinoma of soft tissue and cellular extraskeletal myxoid chondrosarcoma. Virchows Arch. 2012, 460: 621-628. 10.1007/s00428-012-1240-0
Drilon AD, Popat S, Bhuchar G: Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy. Cancer. 2008, 113: 3364-3371. 10.1002/cncr.23978
Patel SR, Burgess MA, Papadopoulos NE: Extraskeletal myxoid chondrosarcoma. Long-term experience with chemotherapy. Am J Clin Oncol. 1995, 18: 161-163. 10.1097/00000421-199504000-00014
McGrory JE, Rock MG, Nascimento AG: Extraskeletal myxoid chondrosarcoma. Clin Orthop Relat Res. 2001, 382: 185-190.
Kawaguchi S, Wada T, Nagoya S: Extraskeletal myxoid chondrosarcoma: a multi-institutional study of 42 cases in Japan. Cancer. 2003, 97: 1285-1292. 10.1002/cncr.11162
Ogura K, Fujiwara T, Beppu Y: Extraskeletal myxoid chondrosarcoma: a review of 23 patients treated at a single referral center with long-term follow-up. Arch Orthop Trauma Surg. 2012, 132: 1379-1386. 10.1007/s00402-012-1557-9
Perrone F, Tabano S, Colombo F: p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Clin Cancer Res. 2003, 9: 4132-4138.
Therasse P, Arbuck SG, Eisenhauer EA: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000, 92: 205-206. 10.1093/jnci/92.3.205
Kaplan WE, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958, 53: 457-481. 10.1080/01621459.1958.10501452.
Han K, Sun YJ, Shen Z: Extraskeletal myxoid chondrosarcoma: a case report of complete remission by chemotherapy and review of the literature. BMJ Case Rep. 2010, doi: 10.1136/bcr.07.2009.2128,
Gelderblom H, Hogendoorn PC, Dijkstra SD: The clinical approach towards chondrosarcoma. Oncologist. 2008, 13 (3): 320-329. 10.1634/theoncologist.2007-0237
Italiano A, Mir O, Cioffi A: Advanced chondrosarcomas: role of chemotherapy and survival. Ann Oncol. 2013, in press,
Hornick JL, Fletcher CD: Myoepithelial tumors of soft tissue: a clinicopathologic and immunohistochemical study of 101 cases with evaluation of prognostic parameters. Am J Surg Pathol. 2003, 27: 1183-1196. 10.1097/00000478-200309000-00001
Subramanian S, West RB, Marinelli RJ: The gene expression profile of extraskeletal myxoid chondrosarcoma. J Pathol. 2005, 206: 433-444. 10.1002/path.1792
Fisher C, Schofield JB: S-100 protein positive synovial sarcoma. Histopathology. 1991, 19: 375-377. 10.1111/j.1365-2559.1991.tb00055.x
Goh YW, Spagnolo DV, Platten M: Extraskeletal myxoid chondrosarcoma: a light microscopic, immunohistochemical, ultrastructural and immuno-ultrastructural study indicating neuroendocrine differentiation. Histopathology. 2001, 39: 514-524. 10.1046/j.1365-2559.2001.01277.x
Filion C, Motoi T, Olshen AB: The EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the PPARG nuclear receptor gene. J Pathol. 2009, 217: 83-93. 10.1002/path.2445
Tontonoz P, Singer S, Forman BM: Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA. 1997, 94: 237-241. 10.1073/pnas.94.1.237
Demetri GD, Fletcher CD, Mueller E: Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA. 1999, 96: 3951-3956. 10.1073/pnas.96.7.3951
Stacchiotti S, Dagrada G, Morosi C: Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib. Clin Sarcoma Res. 2012, 2: 22- 10.1186/2045-3329-2-22